SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

(Name of Issuer)

Class A ordinary shares, par value US\$0.0001 per share

(Title of Class of Securities)

206277 105⁽¹⁾

(CUSIP Number)

SZE Mei Ming

Fosun International Limited

Room 808

Reed Smith Richards Butler

20/F, Alexandra House

3 Garden Road, Central

Hong Kong, China

(852) 2509 3228

With a copy to:
Gregory Wang, Esq.
Reed Smith Richards Butler

20/F, Alexandra House

18 Chater Road, Central
Hong Kong, China
(852) 2507 9869

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 7, 2018

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box \square .

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1) This CUSIP number applies to the Issuer's American depositary shares ("ADSs"), each representing three Class A ordinary shares of the Issuer.

CUSIP No. 206277 105

(1)	NAME OF	REPO	RTING PERSONS
	Fosun Inte	rnationa	l Limited
(2)	CHECK T	HE API	PROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
` '	(a) ⊠		
	(b) □		
(3)	SEC USE	ONLY	
(4)	SOURCE	OF FUI	NDS
	WC		
(5)	CHECK IF	F DISCI	LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) \Box
(6)	CITIZENS	HIP OF	R PLACE OF ORGANIZATION
	Hong Kong	g	
Nu	mber of	(7)	SOLE VOTING POWER
_	Shares		0
	eficially	(8)	SHARED VOTING POWER
	ed by Each		13,086,350
	porting	(9)	SOLE DISPOSITIVE POWER
Pers	son With		0
		(10)	SHARED DISPOSITIVE POWER
			13,086,350
(11)			MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
(15)	13,086,350		
(12)		THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(4.5)	DEDCEM		ACC DEPOPERATION DAY AN OVERT BY DOVE (44)
(13)		OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)
	15.5% ⁽¹⁾		
(14)		REPOR	TING PERSON
	CO		
445			1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(1)	This percer	itage is	calculated based on 84,368,529 Class A ordinary shares, par value \$0.0001 per share (the "Ordinary Shares") of Concord Medical

CUSIP No. 206277 105

(1) NAME OF REPORTING PERSONS

	Fosun Ind	ustrial H	oldings Limited	
(2)	CHECK 7	ГНЕ АРІ	PROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
	(a) ⊠			
	(b) □			
(3)	SEC USE	ONLY		
(4)	SOURCE	OF FUN	NDS .	
/= \	AF			
(5)			LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) □	
(6)	_	_	R PLACE OF ORGANIZATION	
	Hong Kor		COLE MOTIVIC POLITIC	
	mber of	(7)	SOLE VOTING POWER	
	Shares	(0)	O CHARLED MOTING POLITER	
	eficially ed by Each	(8)	SHARED VOTING POWER	
	porting	(0)	13,086,350 SOLE DISPOSITIVE POWER	
	son With	(9)	O	
1 (1)	OII VVIIII	(10)	SHARED DISPOSITIVE POWER	
		(10)	13,086,350	
(11)	ACCDEC	ATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
(11)	13,086,35		MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
(12)			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
(12)		1 111111 1	IGGREGATE ANOCHAL IN NOW (11) EACEODES CERTAIN STRARES	
(13)	PERCEN'	T OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)	
(- /	15.5% ⁽¹⁾			
(14)			TING PERSON	
()	CO			
(1) This percentage is calculated based on 84,368,529 Ordinary Shares of the Issuer outstanding as of December 7, 2018, as disclosed in the Issuer				
	Form 6-K filed with the SEC on December 7, 2018.			

-3-

CUSIP No. 206277 105

(1)	NAME OF	F REPO	RTING PERSONS
	Oasis Insp	ire Limi	ited
(2)	CHECK T	HE API	PROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
	(a) ⊠		
	(b) □		
(3)	SEC USE	ONLY	
(4)	SOURCE	OF FUN	NDS
	AF		
(5)	CHECK II	F DISCI	LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) \Box
(6)			R PLACE OF ORGANIZATION
	British Vir		
	mber of	(7)	SOLE VOTING POWER
_	hares		0
	eficially	(8)	SHARED VOTING POWER
	d by Each		13,086,350
	porting	(9)	SOLE DISPOSITIVE POWER
Pers	on With		0
		(10)	SHARED DISPOSITIVE POWER
			13,086,350
(11)			MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	13,086,350		
(12)		F THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(4.0)	DEDCEM	E OF CI	A CC DEDDECEMEED DV A MOUNTE IN DOW (44)
(13)		OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)
	15.5% ⁽¹⁾		
(14)		REPOR	TING PERSON
	CO		
(1)			
(1)		_	calculated based on 84,368,529 Ordinary Shares of the Issuer outstanding as of December 7, 2018, as disclosed in the Issuer's
	rofili o-K	mea wit	th the SEC on December 7, 2018.

Explanatory Note

This Amendment No. 1 to statement on Schedule 13D (this "Amendment No. 1") amends and supplements the Schedule 13D filed with the SEC on November 13, 2017 (the "Original Schedule 13D", and as amended and supplemented by this Amendment No. 1, the "Schedule 13D"), and is being filed on behalf of the Reporting Persons in respect of the Ordinary Shares of the Issuer.

This Amendment No. 1 is being filed by the Reporting Persons solely to report changes to the beneficial ownership as a result of change in the aggregate number of outstanding Ordinary Shares of the Issuer as reported in its Form 6-K filed with the SEC on December 7, 2018.

Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used but not defined in this Amendment No. 1 have the respective meanings set forth in the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

- (a) See Items 11 and 13 of the cover pages to this Schedule 13D for the aggregate number and percentage of Ordinary Shares that are beneficially owned by each Reporting Person as of January 16, 2019.
- (b) See Items 7 through 10 of the cover pages to this Schedule 13D for the number of Ordinary Shares that are beneficially owned by each Reporting Person as of January 16, 2019 as to which there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition.
 - (c) The Reporting Persons have not effected any transactions in the Ordinary Shares or ADSs during the past 60 days.
- (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Schedule 13D.
 - (e) Not applicable.

Item 7. Material to be Filed as Exhibits.

Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows:

EXHIBIT 99.1 Joint Filing Agreement dated as of November 13, 2017, by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.2 List of the directors and executive officers of each Reporting Person, persons controlling any Reporting Person and the directors and executive officers of persons in control of any Reporting Person.

EXHIBIT 99.3 Share Purchase Agreement dated October 31, 2017 (incorporated by reference to Exhibit 99.3 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.4 Controlling Shareholder's Undertaking Letter dated October 31, 2017 (incorporated by reference to Exhibit 99.4 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.5 Issuer's Undertaking Letter dated October 31, 2017 (incorporated by reference to Exhibit 99.5 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 16, 2019

FOSUN INTERNATIONAL LIMITED

By: /s/ SZE Mei Ming
Name: SZE Mei Ming
Title: Company Secretary

FOSUN INDUSTRIAL HOLDINGS LIMITED

By: /s/ CHEN Qiyu
Name: CHEN Qiyu
Title: Director

OASIS INSPIRE LIMITED

By: /s/ Yanxiang LU
Name: Yanxiang LU
Title: Director

Fosun International Limited

Name	Business Address	Present Principal Employment	Citizenship
Guo Guangchang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Chairman of Fosun International	China
Wang Qunbin	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Chief Executive Officer of Fosun International	China
Chen Qiyu	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-President of Fosun International	China
Xu Xiaoliang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-President of Fosun International	China
Qin Xuetang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Senior Vice President of Fosun International	China
Wang Can	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director, Senior Vice President and Chief Financial Officer of Fosun International	China
Gong Ping	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Senior Vice President of Fosun International	China
Zhang Shengman	N/A	Independent Non-executive Director of Fosun International	Hong Kong
Zhang Huaqiao	N/A	Independent Non-executive Director of Fosun International	Hong Kong
David T. Zhang	26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong	Independent Non-executive Director of Fosun International; Partner of Kirkland & Ellis LLP	Hong Kong
Yang Chao	N/A	Independent Non-executive Director of Fosun International	China
Lee Kai-Fu	10/F, Dinghao Tower Block A, No. 3 Haidian Street, Haidian District, Beijing, China	Independent Non-executive Director of Fosun International; Chairman of Sinovation Ventures (Beijing) Enterprise Management Co., Ltd.	Republic of China

Fosun Industrial Holdings Limited

Business Address	Present Principal Employment	Citizenship
Room 808, ICBC Tower, 3 Garden Road, Central,	Director of Fosun Industrial Holdings Limited	China
Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director of Fosun Industrial Holdings Limited	Hong Kong
Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director of Fosun Industrial Holdings Limited	Hong Kong
3	Loom 808, ICBC Tower, 3 Garden Road, Central, long Kong Loom 808, ICBC Tower, 3 Garden Road, Central, long Kong Loom 808, ICBC Tower, 3 Garden Road, Central, long Kong	Loom 808, ICBC Tower, 3 Garden Road, Central, Director of Fosun Industrial Holdings Limited Loom 808, ICBC Tower, 3 Garden Road, Central, Iong Kong Loom 808, ICBC Tower, 3 Garden Road, Central, Iong Kong Loom 808, ICBC Tower, 3 Garden Road, Central, Director of Fosun Industrial Holdings Limited Loom 808, ICBC Tower, 3 Garden Road, Central, Director of Fosun Industrial Holdings Limited

Fosun Industrial Holdings Limited is wholly owned by Fosun International Limited as of January 16, 2019.

Oasis Inspire Limited

Name	Business Address	Present Principal Employment	Citizenship
Yanxiang LU	17/F, Tower S1, Bund Finance Center, 600 East Zhongshan No.2 Road, Shanghai, China	Director of Oasis Inspire Limited	Hong Kong

Oasis Inspire Limited is directly wholly owned by Fosun Industrial Holdings Limited and indirectly wholly owned by Fosun International Limited as of January 16, 2019.